Thioredoxin interacting protein: Redox dependent and independent regulatory mechanisms

Antioxidants and Redox Signaling

Volumn 16, Issue 6, 2012, Pages 587-596

  Spindel, Oded N ^a   World, Cameron ^a   Berk, Bradford C ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ARRESTIN; APOPTOSIS SIGNAL REGULATING KINASE 1; BETA ARRESTIN; CYCLIN DEPENDENT KINASE INHIBITOR; GLUCOSE; INSULIN; INTERLEUKIN 1BETA; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 11; PROTEIN P300; THIOREDOXIN INTERACTING PROTEIN; TRANSCRIPTION FACTOR FKHR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR 2;

AMINO ACID SEQUENCE; APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; DIABETES MELLITUS; GENETIC DISORDER; GLUCONEOGENESIS; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; INSULIN SENSITIVITY; LIPOGENESIS; LIVER FUNCTION; METABOLIC SYNDROME X; NONHUMAN; NONSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; STRUCTURE ACTIVITY RELATION; UBIQUITINATION; VASCULARIZATION;

ANIMALS; CARRIER PROTEINS; HUMANS; MICE; OXIDATION-REDUCTION; THIOREDOXINS;

EID: 84856756649     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4137     Document Type: Review

References (84)

1. Adair-KirkTL, Atkinson JJ, GriffinGL,WatsonMA, KelleyDG, DeMello D, Senior RM, and Betsuyaku T. Distal airways in mice exposed to cigarette smoke: Nrf2-regulated genes are increased inClara cells.AmJRespirCellMolBiol 39: 400-411, 2008.
2. Ago T, Liu T, Zhai P, Chen W, Li H, Molkentin JD, Vatner SF, and Sadoshima J. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 133: 978-993, 2008. (Pubitemid 351787743)
3. Alvarez CE. On the origins of arrestin and rhodopsin. BMC Evol Biol 8: 222, 2008.
4. Barrow AD and Trowsdale J. You say ITAM and I say ITIM, let's call the whole thing off: the ambiguity of immunoreceptor signalling. Eur J Immunol 36: 1646-1653, 2006. (Pubitemid 44089030)
5. Bodnar JS, Chatterjee A, Castellani LW, Ross DA, Ohmen J, Cavalcoli J, Wu C, Dains KM, Catanese J, Chu M, Sheth SS, Charugundla K, Demant P, West DB, de Jong P, and Lusis AJ. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nat Genet 30: 110-116, 2002.
6. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, and Richon VM. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxinbinding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 99: 11700-11705, 2002. (Pubitemid 34994462)
7. Cadenas C, Franckenstein D, Schmidt M, Gehrmann M, Hermes M, Geppert B, Schormann W, Maccoux LJ, Schug M, Schumann A, Wilhelm C, Freis E, Ickstadt K, Rahnenfuhrer J, Baumbach JI, Sickmann A, and Hengstler JG. Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res 12: R44, 2010.
8. Castellani LW, Weinreb A, Bodnar J, Goto AM, Doolittle M, Mehrabian M, Demant P, and Lusis AJ. Mapping a gene for combined hyperlipidaemia in a mutant mouse strain. Nat Genet 18: 374-377, 1998. (Pubitemid 28158168)
9. Chai TF, Leck YC, He H, Yu FX, Luo Y, and Hagen T. Hypoxia-inducible factor independent down-regulation ofthioredoxin-interact ng protein in hypoxia. FEBS Lett 585: 492-498, 2011.
10. Chen CL, Lin CF, Chang WT, Huang WC, Teng CF, and Lin YS. Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated pathway. Blood 111: 4365-4374, 2008.
11. Chen J, Cha-Molstad H, Szabo A, and Shalev A. Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein. Am J Physiol Endocrinol Metab 296: E1133-E1139, 2009.
12. Chen J, Fontes G, Saxena G, Poitout V, and Shalev A. Lack of TXNIP protects against mitochondria-mediated apoptosis but not against fatty acid-induced ER stress-mediated betacell death. Diabetes 59: 440-447, 2010.
13. Chen J, Hui ST, Couto FM, Mungrue IN, Davis DB, Attie AD, Lusis AJ, Davis RA, and Shalev A. Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes. FASEB J 22: 3581-3594, 2008.
14. Chen J, Saxena G, Mungrue IN, Lusis AJ, and Shalev A. Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis. Diabetes 57: 938-944, 2008.
15. Chen KS and DeLuca HF. Cloning of the human 1 alpha,25- dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim Biophys Acta 1263: 1-9, 1995.
16. Chutkow WA, Birkenfeld AL, Brown JD, Lee HY, Frederick DW, Yoshioka J, Patwari P, Kursawe R, Cushman SW, Plutzky J, Shulman GI, Samuel VT, and Lee RT. Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. Diabetes 59: 1424-1434, 2010.
17. Chutkow WA and Lee RT. Thioredoxin regulates adipogenesis through thioredoxin interacting protein (Txnip) protein stability. J Biol Chem 286: 29139-29145, 2011.
18. Chutkow WA, Patwari P, Yoshioka J, and Lee RT. Thioredoxin- interacting Protein (Txnip) Is a Critical Regulator of Hepatic Glucose Production. J Biol Chem 283: 2397-2406, 2008.
19. Dansen TB, Smits LM, van Triest MH, de Keizer PL, van Leenen D, Koerkamp MG, Szypowska A, Meppelink A, Brenkman AB, Yodoi J, Holstege FC, and Burgering BM. Redox-sensitive cysteines bridge p300/CBP-mediated acetylation and FoxO4 activity. Nat Chem Biol 5: 664-672, 2009.
20. Donnelly KL, Margosian MR, Sheth SS, Lusis AJ, and Parks EJ. Increased lipogenesis and fatty acid reesterification contribute to hepatic triacylglycerol stores in hyperlipidemic Txnip-/- mice. J Nutr 134: 1475-1480, 2004. (Pubitemid 38720724)
21. Dunn LL, Buckle AM, Cooke JP, and Ng MK. The emerging role of the thioredoxin system in angiogenesis. Arterioscler Thromb Vasc Biol 30: 2089-2098, 2010.
22. Dutta KK, Nishinaka Y, Masutani H, Akatsuka S, Aung TT, Shirase T, Lee WH, Yamada Y, Hiai H, Yodoi J, and Toyokuni S. Two distinct mechanisms for loss of thioredoxinbinding protein-2 in oxidative stress-induced renal carcinogenesis. Lab Invest 85: 798-807, 2005. (Pubitemid 40799709)
23. Farrell MR, Rogers LK, Liu Y, Welty SE, and Tipple TE. Thioredoxin-interacting protein inhibits hypoxia-inducible factor transcriptional activity. Free Radic Biol Med 49: 1361-1367, 2010.
24. Holmgren A and Bjornstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol 252: 199-208, 1995.
25. Hui ST, Andres AM, Miller AK, Spann NJ, Potter DW, Post NM, Chen AZ, Sachithanantham S, Jung DY, Kim JK, and Davis RA. Txnip balances metabolic and growth signaling via PTEN disulfide reduction. Proc Natl Acad Sci U S A 105: 3921-3926, 2008. (Pubitemid 351723500)
26. Hui TY, Sheth SS, Diffley JM, Potter DW, Lusis AJ, Attie AD, and Davis RA. Mice lacking thioredoxin-interacting protein provide evidence linking cellular redox state to appropriate response to nutritional signals. J Biol Chem 279: 24387-24393, 2004. (Pubitemid 38725301)
27. Jeon JH, Lee KN, Hwang CY, Kwon KS, You KH, and Choi I. Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1. Cancer Res 65: 4485-4489, 2005. (Pubitemid 40740780)
28. Jin HO, Seo SK, Kim YS, Woo SH, Lee KH, Yi JY, Lee SJ, Choe TB, Lee JH, An S, Hong SI, and Park IC. TXNIP potentiates Redd1-induced mTOR suppression through stabilization of Redd1. Oncogene 30: 3792-3801, 2011.
29. Kopantzev EP, Monastyrskaya GS, Vinogradova TV, Zinovyeva MV, Kostina MB, Filyukova OB, Tonevitsky AG, Sukhikh GT, and Sverdlov ED. Differences in gene expression levels between early and later stages of human lung development are opposite to those between normal lung tissue and non-small lung cell carcinoma. Lung Cancer 62: 23-34, 2008.
30. Kuljaca S, Liu T,Dwarte T, Kavallaris M, Haber M, Norris MD, Martin-Caballero J, and Marshall GM. The cyclin-dependent kinase inhibitor, p21(WAF1), promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells. Carcinogenesis 30: 1865-1871, 2009.
31. Kwon HJ, Won YS, Suh HW, Jeon JH, Shao Y, Yoon SR, Chung JW, Kim TD, Kim HM, Nam KH, Yoon WK, Kim DG, Kim JH, Kim YS, Kim DY, Kim HC, and Choi I. Vitamin D3 upregulated protein 1 suppresses TNF-alpha-induced NFkappaB activation in hepatocarcinogenesis. J Immunol 185: 3980-3989, 2010.
32. Laporte SA, Oakley RH, Holt JA, Barak LS, and Caron MG. The interaction of beta-arrestin with the AP-2 adaptor is required for the clustering of beta 2-adrenergic receptor into clathrin-coated pits. J Biol Chem 275: 23120-23126, 2000. (Pubitemid 30646204)
33. Lee JH, Jeong EG, Choi MC, Kim SH, Park JH, Song SH, Park J, Bang YJ, and Kim TY. Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells. Mol Cells 30: 107-112, 2010.
34. Li X, Rong Y, Zhang M, Wang XL, LeMaire SA, Coselli JS, Zhang Y, and Shen YH. Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells. Biochem Biophys Res Commun 381: 660-665, 2009.
35. Lillig CH and Holmgren A. Thioredoxin and related molecules- from biology to health and disease. Antioxid Redox Signal 9: 25-47, 2007. (Pubitemid 44901873)
36. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK, Caron MG, and Lefkowitz RJ. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283: 655-661, 1999.
37. Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, Happel C, Shyr C, Wakabayashi N, Kensler TW, Wasserman WW, and Biswal S. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 38: 5718-5734, 2010.
38. Masson E, Koren S, Razik F, Goldberg H, Kwan EP, Sheu L, Gaisano HY, and Fantus IG. High beta-cell mass preventsstreptozotocin-induced dibetes in thioredoxin-interacting protein-deficient mice. Am J Physiol Endocrinol Metab 296: E1251-E1261, 2009.
39. Matsuoka S, Tsuchiya H, Sakabe T, Watanabe Y, Hoshikawa Y, Kurimasa A, Itamochi H, Harada T, Terakawa N, Masutani H, Yodoi J, and Shiota G. Involvement of thioredoxinbinding protein 2 in the antitumor activity of CD437. Cancer Sci 99: 2485-2490, 2008.
40. Miller WE, McDonald PH, Cai SF, Field ME, Davis RJ, and Lefkowitz RJ. Identification of a motif in the carboxyl terminus of beta -arrestin2 responsible for activation of JNK3. J Biol Chem 276: 27770-27777, 2001.
41. Minn AH, Hafele C, and Shalev A. Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 146: 2397-2405, 2005. (Pubitemid 40577527)
42. Nishinaka Y, Masutani H, Oka S, Matsuo Y, Yamaguchi Y, Nishio K, Ishii Y, and Yodoi J. Importin alpha1 (Rch1) mediates nuclear translocation of thioredoxin-binding protein- 2/vitamin D(3)-up-regulated protein 1. J Biol Chem 279: 37559-37565, 2004. (Pubitemid 39195469)
43. Nishinaka Y, Nishiyama A, Masutani H, Oka S, Ahsan KM, Nakayama Y, Ishii Y, Nakamura H, Maeda M, and Yodoi J. Loss of thioredoxin-binding protein-2/vitamin D3 upregulated protein 1 in human T-cell leukemia virus type Idependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis. Cancer Res 64: 1287-1292, 2004. (Pubitemid 38235595)
44. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y, and Yodoi J. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274: 21645-21650, 1999.
45. Nivet-Antoine V, Cottart CH, Lemarechal H, Vamy M, Margaill I, Beaudeux JL, Bonnefont-Rousselot D, and Borderie D. trans-Resveratrol downregulates Txnip overexpression occurring during liver ischemia-reperfusion. Biochimie 92: 1766-1771, 2010.
46. Obikane H, Abiko Y, Ueno H, Kusumi Y, Esumi M, and Mitsumata M. Effect of endothelial cell proliferation on atherogenesis: a role of p21(Sdi/Cip/Waf1) in monocyte adhesion to endothelial cells. Atherosclerosis 212: 116-122, 2010.
47. Oka S, Liu W, Yoshihara E, Ahsan MK, Ramos DA, Son A, Okuyama H, Zhang L, Masutani H, Nakamura H, and Yodoi J. Thioredoxin binding protein-2 mediates metabolic adaptation in response to lipopolysaccharide in vivo. Crit Care Med 38: 2345-2351, 2010.
48. Oka S, Yoshihara E, Bizen-Abe A, Liu W, Watanabe M, Yodoi J, and Masutani H. Thioredoxin binding protein-2/ thioredoxin-interacting protein is a critical regulator of insulin secretion and peroxisome proliferator-activated receptor function. Endocrinology 150: 1225-1234, 2009.
49. Okuyama H, Yoshida T, Son A, Oka S, Wang D, Nakayama R, Masutani H, Nakamura H, Nabeshima Y, and Yodoi J. Thioredoxin binding protein 2 modulates natural killer T cell-dependent innate immunity in the liver: possible link to lipid metabolism. Antioxid Redox Signal 11: 2585-2593, 2009.
50. Parikh H, Carlsson E, Chutkow WA, Johansson LE, Storgaard H, Poulsen P, Saxena R, Ladd C, Schulze PC, Mazzini MJ, Jensen CB, Krook A, Bjornholm M, Tornqvist H, Zierath JR, Ridderstrale M, Altshuler D, Lee RT, Vaag A, Groop LC, and Mootha VK. TXNIP regulates peripheral glucose metabolism in humans. PLoS Med 4: e158, 2007.
51. Patwari P, Chutkow WA, Cummings K, Verstraeten VL, Lammerding J, Schreiter ER, and Lee RT. Thioredoxinindependent regulation of metabolism by the alpha-arrestin proteins. J Biol Chem 284: 24996-25003, 2009.
52. Patwari P, Higgins LJ, Chutkow WA, Yoshioka J, and Lee RT. The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem 281: 21884-21891, 2006. (Pubitemid 44181892)
53. Perrone L, Devi TS, Hosoya K, Terasaki T, and Singh LP. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol 221: 262-272, 2009.
54. Peterson CW, Stoltzman CA, Sighinolfi MP, Han KS, and Ayer DE. Glucose controls nuclear accumulation, promoter binding, and transcriptional activity of the MondoA-Mlx heterodimer. Mol Cell Biol 30: 2887-2895, 2010.
55. Qi W, Chen X, Holian J, Tan CY, Kelly DJ, and Pollock CA. Transcription factors Kruppel-like factor 6 and peroxisome proliferator-activated receptor-{gamma} mediate high glucose- induced thioredoxin-interacting protein. Am J Pathol 175: 1858-1867, 2009.
56. Rani S, Mehta JP, Barron N, Doolan P, Jeppesen PB, Clynes M, and O'Driscoll L. Decreasing Txnip mRNA and protein levels in pancreatic MIN6 cells reduces reactive oxygen species and restores glucose regulated insulin secretion. Cell Physiol Biochem 25: 667-674, 2010.
57. Rauch S and Martin-Serrano J. Multiple Interactions between the ESCRT Machinery and Arrestin-Related Proteins: Implications for PPXY-Dependent Budding. J Virol 85: 3546-3556, 2011.
58. Saxena G, Chen J, and Shalev A. Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. J BIol Chem 285: 3997-4005, 2010.
59. Schroeder P, Popp R, Wiegand B, Altschmied J, and Haendeler J. Nuclear redox-signaling is essential for apoptosis inhibition in endothelial cells-important role for nuclear thioredoxin-1. Arterioscler Thromb Vasc Biol 27: 2325-2331, 2007. (Pubitemid 350203946)
60. Schulze PC, De Keulenaer GW, Yoshioka J, Kassik KA, and Lee RT. Vitamin D3-upregulated protein-1 (VDUP-1) regulates redox- dependent vascular smooth muscle cell proliferation through interactionwith thioredoxin. Circ Res 91: 689-695, 2002. (Pubitemid 35204951)
61. Schulze PC, Liu H, Choe E, Yoshioka J, Shalev A, Bloch KD, and Lee RT. Nitric oxide-dependent suppression of thioredoxin- interacting protein expression enhances thioredoxin activity. Arterioscler Thromb Vasc Biol 26: 2666-2672, 2006.
62. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, and Lee RT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 279: 30369-30374, 2004. (Pubitemid 38937964)
63. Shao W, Yu Z, Fantus IG, and Jin T. Cyclic AMP signaling stimulates proteasome degradation of thioredoxin interacting protein (TxNIP) in pancreatic beta-cells. Cell Signal 22: 1240-1246, 2010.
64. Shin D, Jeon JH, Jeong M, Suh HW, Kim S, Kim HC, Moon OS, Kim YS, Chung JW, Yoon SR, Kim WH, and Choi I. VDUP1 mediates nuclear export of HIF1alpha via CRM1-dependent pathway. Biochim Biophys Acta 1783: 838-848, 2008.
65. Stoltzman CA, Peterson CW, Breen KT, Muoio DM, Billin AN, and Ayer DE. Glucose sensing by MondoA:Mlx complexes: a role for hexokinases and direct regulation of thioredoxin-interacting protein expression. Proc Natl Acad Sci U S A 105: 6912-6917, 2008. (Pubitemid 351754504)
66. Takahashi Y, Nagata T, Ishii Y, Ikarashi M, Ishikawa K, and Asai S. Up-regulation of vitamin D3 up-regulated protein 1 gene in response to 5-fluorouracil in colon carcinoma SW620. Oncol Rep 9: 75-79, 2002.
67. Thomas SR, Witting PK, and Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 10: 1713-1765, 2008.
68. Ushio-Fukai M. Vascular signaling through G proteincoupled receptors: new concepts. Curr Opin Nephrol Hypertens 18: 153-159, 2009.
69. Wang Y, De Keulenaer GW, and Lee RT. Vitamin D(3)-upregulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. J Biol Chem 277: 26496-26500, 2002. (Pubitemid 34967145)
70. Wang Z, Rong YP, Malone MH, Davis MC, Zhong F, and Distelhorst CW. Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis. Oncogene 25: 1903-1913, 2006.
71. World C, Spindel ON, and Berk BC. Thioredoxin-interacting protein mediates TRX1 translocation to the plasma membrane in response to tumor necrosis factor-{alpha}: a key mechanism for vascular endothelial growth factor receptor-2 transactivation by reactive oxygen species. Arterioscler Thromb Vasc Biol, 2011.
72. World CJ, Yamawaki H, and Berk BC. Thioredoxin in the cardiovascular system. J Mol Med 84: 997-1003, 2006.
73. Xiang G, Seki T, Schuster MD, Witkowski P, Boyle AJ, See F, Martens TP, Kocher A, Sondermeijer H, Krum H, and Itescu S. Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodeling after myocardial ischemia. J Biol Chem 280: 39394-39402, 2005. (Pubitemid 41713897)
74. Yamaguchi F, Takata M, Kamitori K, Nonaka M, Dong Y, Sui L, and Tokuda M. Rare sugar D-allose induces specific up-regulation of TXNIP and subsequent G1 cell cycle arrest in hepatocellular carcinoma cells by stabilization of p27kip1. Int J Oncol 32: 377-385, 2008. (Pubitemid 351188304)
75. Yamawaki H and Berk BC. Thioredoxin: a multifunctional antioxidant enzyme in kidney, heart and vessels. Curr Opin Nephrol Hypertens 14: 149-153, 2005. (Pubitemid 40396868)
76. Yamawaki H, Pan S, Lee RT, and Berk BC. Fluid shear stress inhibits vascular inflammation by decreasing thioredoxininteracting protein in endothelial cells. J Clin Invest 115: 733-738, 2005. (Pubitemid 40322249)
77. Yoshihara E, Fujimoto S, Inagaki N, Okawa K, Masaki S, Yodoi J, and Masutani H. Disruption of TBP-2 ameliorates insulin sensitivity and secretion without affecting obesity. Nat Commun 1: 127, 2010.
78. Yoshioka J, Imahashi K, Gabel SA, Chutkow WA, Burds AA, Gannon J, Schulze PC, MacGillivray C, London RE, Murphy E, and Lee RT. Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. Circ Res 101: 1328-1338, 2007. (Pubitemid 350294650)
79. Yoshioka J, Schulze PC, Cupesi M, Sylvan JD, MacGillivray C, Gannon J, Huang H, and Lee RT. Thioredoxin-interacting protein controls cardiac hypertrophy through regulation of thioredoxin activity. Circulation 109: 2581-2586, 2004. (Pubitemid 38720560)
80. Yu FX, Chai TF, He H, Hagen T, and Luo Y. Thioredoxininteracting protein (Txnip) gene expression: sensing oxidative phosphorylation status and glycolytic rate. J Biol Chem 285: 25822-25830, 2010.
81. Yu FX, Goh SR, Dai RP, and Luo Y. Adenosine-containing molecules amplify glucose signaling and enhance txnip expression. Mol Endocrinol 23: 932-942, 2009.
82. Zhang P, Wang C, Gao K, Wang D, Mao J, An J, Xu C, Wu D, Yu H, Liu JO, and Yu L. The ubiquitin ligase itch regulates apoptosis by targeting thioredoxin-interacting protein for ubiquitin-dependent degradation. J Biol Chem 285: 8869-8879, 2010.
83. Zhou R, Tardivel A, Thorens B, Choi I, and Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11: 136-140, 2010.
84. Zitman-Gal T, Green J, Pasmanik-Chor M, Oron-Karni V, and Bernheim J. Endothelial pro-atherosclerotic response to extracellular diabetic-like environment: possible role of thioredoxin-interacting protein. Nephrol Dial Transplant 25: 2141-2149, 2010.